secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001714899-23-000074
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Q1 net loss widens to $109.8M; Biogen licenses ATV:Abeta, DNL310 positive data
--------------------------------------------------------------------------------

- Net loss $109.8M vs $65.2M YoY; collaboration revenue $35.1M vs $42.1M.
- R&D expenses rose to $128.8M from $86.1M; cash & securities $1.29B at March 31.
- Biogen exercised option to license ATV:Abeta; Denali receives option payment and milestones.
- DNL310 Phase 1/2 interim data showed improved behavior/cognition; COMPASS study enrolling.
- Triggered $30M contingent consideration for F-star Gamma; $10M milestone from Takeda for DNL593.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000074/0001714899-23-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000074/dnli-20230508.htm
  HTML page:      https://secwatch.observer/filing/0001714899-23-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer